GW Pharmaceuticals (GW) is a British biopharmaceuticals company now owned by Jazz Pharmaceuticals. GW is focused on developing and marketing therapeutics based on plant-derived cannabinoid compounds. GW saw early success with Epidolex, the first cannabis plant-derived medicine approved by the FDA, which is used to treat patients with rare epilepsy diseases (Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex). GW has also developed Sativex, which is used to treat patients with multiple sclerosis. GW is primarily focused on neurological conditions, including conditions with both orphan and non-orphan status.